IsoPlexis (NASDAQ:ISO) Price Target Cut to $2.50

IsoPlexis (NASDAQ:ISOGet Rating) had its target price dropped by equities research analysts at SVB Leerink from $3.00 to $2.50 in a report issued on Friday, Marketbeat.com reports. The brokerage currently has a “market perform” rating on the stock. SVB Leerink’s target price would indicate a potential upside of 61.29% from the stock’s current price.

Separately, Morgan Stanley cut IsoPlexis from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $8.00 to $5.00 in a research report on Thursday, August 11th.

IsoPlexis Stock Up 2.6 %

NASDAQ ISO opened at $1.55 on Friday. IsoPlexis has a one year low of $1.51 and a one year high of $16.95. The stock has a 50-day moving average of $1.83 and a 200 day moving average of $2.23. The company has a current ratio of 10.20, a quick ratio of 6.78 and a debt-to-equity ratio of 0.51.

IsoPlexis (NASDAQ:ISOGet Rating) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.02). IsoPlexis had a negative return on equity of 159.40% and a negative net margin of 535.02%. The business had revenue of $4.01 million during the quarter, compared to the consensus estimate of $5.64 million. As a group, analysts forecast that IsoPlexis will post -2.19 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Richard W. Rew II acquired 20,000 shares of IsoPlexis stock in a transaction on Thursday, August 25th. The shares were acquired at an average price of $1.99 per share, with a total value of $39,800.00. Following the purchase, the senior vice president now directly owns 20,000 shares in the company, valued at approximately $39,800. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Sean Mackay acquired 15,000 shares of IsoPlexis stock in a transaction on Thursday, August 25th. The shares were acquired at an average price of $1.99 per share, with a total value of $29,850.00. Following the purchase, the chief executive officer now directly owns 914,366 shares in the company, valued at approximately $1,819,588.34. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Richard W. Rew II acquired 20,000 shares of IsoPlexis stock in a transaction on Thursday, August 25th. The stock was purchased at an average cost of $1.99 per share, for a total transaction of $39,800.00. Following the purchase, the senior vice president now owns 20,000 shares in the company, valued at $39,800. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 65,506 shares of company stock valued at $128,406. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On IsoPlexis

Several hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new stake in shares of IsoPlexis in the 1st quarter worth $36,000. Corient Capital Partners LLC purchased a new stake in shares of IsoPlexis in the 2nd quarter worth $25,000. Quadrant Private Wealth Management LLC lifted its stake in shares of IsoPlexis by 180.9% during the 1st quarter. Quadrant Private Wealth Management LLC now owns 31,053 shares of the company’s stock worth $107,000 after purchasing an additional 20,000 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of IsoPlexis during the 1st quarter worth $103,000. Finally, Vanguard Group Inc. lifted its stake in shares of IsoPlexis by 10.6% during the 1st quarter. Vanguard Group Inc. now owns 335,282 shares of the company’s stock worth $1,150,000 after purchasing an additional 32,114 shares during the last quarter. 48.70% of the stock is currently owned by hedge funds and other institutional investors.

About IsoPlexis

(Get Rating)

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea.

Featured Articles

Receive News & Ratings for IsoPlexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoPlexis and related companies with MarketBeat.com's FREE daily email newsletter.